Research Report for Investors: Regulus Therapeutics Inc. (NASDAQ:RGLS)

4

Regulus Therapeutics Inc. (NASDAQ:RGLS) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.

Regulus Therapeutics Inc. (NASDAQ:RGLS) lost -9.42 Percent and closed its previous trading session at $0.22. The stock traded with the average Volume of 630.8 Million at the end of last session.

Regulus Therapeutics Inc. (NASDAQ:RGLS) has the Market Capitalization of 22.67 Million. The Stock has its 52-week High of $1.520 and 52-Week Low of $0.220 and it touched its 52-week high on 10/02/17 and 52-Week Low on 08/08/18

.

The company reported its last earnings Actual EPS of $-0.15/share. While, the analyst predicted that the company could provide an EPS of $-0.15/share.

Sell side analysts plays vital role in buying and selling a stock where 1 analysts rated Regulus Therapeutics Inc. (NASDAQ:RGLS) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -21.41% where SMA50 and SMA200 are -56.36% and -73.77% respectively.

The company shows its Return on Assets (ROA) value of -92.8%. The Return on Equity (ROE) value stands at -214.4%.

Regulus Therapeutics Inc. (NASDAQ:RGLS) currently has a Weekly Volatility of 12.21% percent while its Monthly Volatility is at 12.01% percent. While talking about Performance of the Stock, Regulus Therapeutics Inc. currently has a Weekly performance of -18.78%, monthly performance percentage is -32.67 percent, Quarterly performance is -69.57 percent, 6 months performance shows a percent value of -80.52% and Yearly Performance is -75.56 percent.

Company Profile:

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California.

SHARE